New Study Finds CEFALY Has Very High Efficacy for Migraine Prevention
NEW YORK, Aug. 26, 2015 /PRNewswire/ — A new study finds that Cefaly, the first FDA-approved transcutaneous electrical nerve stimulation device specifically authorized for use prior to the onset of migraine pain, provides relief for 81% of migraine sufferers who use it. read more
Gilead Results From the AMBITION Study of First-Line Treatment With Letairis and Tadalafil in Pulmonary Arterial Hypertension Published in The New England Journal of Medicine – See more at: http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=2082387#sthash.f42bCW9v.dpuf
FOSTER CITY, Calif.–(BUSINESS WIRE)–Aug. 26, 2015– Gilead Sciences, Inc. (Nasdaq: GILD) today announced detailed results from the AMBITION study (a randomized, double-blind, multicenter study of first-line combination therapy with AMBrIsentan and Tadalafil in patients with pulmonary arterial hypertensION). In AMBITION, conducted in collaboration with GlaxoSmithKline (GSK), combination therapy with Letairis® (ambrisentan) and tadalafil reduced the risk of clinical failure by 50 percent compared to the pooled Letairis and tadalafil monotherapy arm (hazard ratio = 0.50; 95 percent CI: 0.35, 0.72; p<0.001). These data were published in The New England Journal of Medicine. – See more at: http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=2082387#sthash.f42bCW9v.dpuf read more
Exelixis Announces First Regulatory Approval of Cobimetinib in Switzerland
SAN FRANCISCO, Calif.–(EON: Enhanced Online News)–Exelixis, Inc. (NASDAQ:EXEL) today announced that Swissmedic, the Swiss licensing and supervisory authority of Switzerland, has approved cobimetinib for use in combination with vemurafenib as a treatment for patients with advanced melanoma. Cobimetinib is a selective inhibitor of MEK that was discovered by Exelixis and is the subject of a worldwide collaboration agreement between Exelixis and Genentech, a member of the Roche Group. The trade name for cobimetinib in Switzerland is Cotellic™. read more
Allied-Bristol Life Sciences Licenses Platform Technology and Lead Molecules from Yale University
BOSTON–(EON: Enhanced Online News)–Allied-Bristol Life Sciences, LLC, a biopharmaceutical enterprise jointly owned between Allied Minds (LSE: ALM) and Bristol-Myers Squibb Company (NYSE: BMY), announced that it has entered into a worldwide licensing agreement with Yale University for a proprietary platform technology and associated lead molecules that will be further developed to treat diseases such as prostate cancer, a leading cause of cancer-related deaths among American men. read more
Novo Nordisk to acquire Calibrium LLC and MB2 LLC
Bagsværd, Denmark, 27 August 2015 – Novo Nordisk today announced that it has entered into a definitive agreement under which Novo Nordisk will acquire Calibrium LLC and MB2 LLC, two privately held biopharmaceutical research companies based in Indiana, US.
Formed in 2013 and 2014, respectively, Calibrium and MB2 are focused on developing a portfolio of novel drug candidates for the treatment of diabetes and related metabolic diseases. The acquisition will expand Novo Nordisk’s portfolio of projects and intellectual property rights within diabetes and obesity and provide a basis for expanding Novo Nordisk’s research presence in the US.
Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk says: “We are always on the lookout for ways to strengthen our leadership position within therapeutic proteins. This research team has demonstrated world-class capabilities in protein design and created a project portfolio of innovative product leads that fit very well with our aspirations within diabetes and obesity.”
Dr Richard DiMarchi, chief scientific officer and co-founder of Calibrium and MB2 says: “It’s an honour to join the global Novo Nordisk research community. Their intense focus on metabolic diseases, which over the years has led to numerous breakthrough protein-based medicines, aligns perfectly with my career-long priorities. I’m optimistic that together we can create novel, transformative therapies in the fight against the global epidemic of diabetes and obesity.”
The parties have agreed not to disclose the financial details of the transactions.
The closing of the transaction is subject to US regulatory approval and is expected to occur during the third quarter of 2015.
For leading medical news and career advice subscribe to Med Career News